Gordon E Guyer Net Worth

The estimated Net Worth of Gordon E Guyer is at least $578 Tysiąc dollars as of 21 December 2009. Gordon Guyer owns over 12,000 units of Neogen stock worth over $485,484 and over the last 21 years Gordon sold NEOG stock worth over $92,017.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gordon Guyer NEOG stock SEC Form 4 insiders trading

Gordon has made over 7 trades of the Neogen stock since 2004, according to the Form 4 filled with the SEC. Most recently Gordon exercised 12,000 units of NEOG stock worth $104,760 on 21 December 2009.

The largest trade Gordon's ever made was exercising 12,501 units of Neogen stock on 6 November 2008 worth over $94,383. On average, Gordon trades about 2,463 units every 160 days since 2003. As of 21 December 2009 Gordon still owns at least 31,835 units of Neogen stock.

You can see the complete history of Gordon Guyer stock trades at the bottom of the page.

What's Gordon Guyer's mailing address?

Gordon's mailing address filed with the SEC is , , , , .

Insiders trading at Neogen

Over the last 24 years, insiders at Neogen have traded over $135,917,555 worth of Neogen stock and bought 195,554 units worth $4,379,833 . The most active insiders traders include James L Herbert, Jeffrey D Capello oraz Lon M Bohannon. On average, Neogen executives and independent directors trade stock every 11 days with the average trade being worth of $140,346. The most recent stock trade was executed by Ronald D Green on 29 August 2024, trading 4,446 units of NEOG stock currently worth $68,780.

What does Neogen do?

neogen corporation develops and markets products dedicated to food and animal safety. the company’s food safety division markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases and sanitation concerns. neogen’s animal safety division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants and rodenticides.

Complete history of Gordon Guyer stock trades at Neogen

Neogen executives and stock owners

Neogen executives and other stock owners filed with the SEC include:

• John Adent,
  President, Chief Executive Officer, Director
• Steven Quinlan,
  Chief Financial Officer, Vice President, Secretary
• John Edward Adent,
  Pres, CEO & Director
• Jason Lilly,
  Vice President - International Business
• Jerome Hagedorn,
  Vice President - Food Safety operations
• Douglas E. Jones,
  VP & Chief Commercial Officer
• Steven J. Quinlan,
  VP & CFO
• James Borel,
  Lead Independent Chairman of the Board
• James Tobin,
  Independent Director
• Ronald Green,
  Independent Director
• William Boehm,
  Independent Director
• Darci Vetter,
  Independent Director
• G. Bruce Papesh,
  Independent Director
• Doug Jones,
  Chief Commercial Officer
• Amy M. Rocklin Ph.D.,
  VP, Gen. Counsel & Corp. Sec.
• Julie A. Mann,
  VP & Chief HR Officer
• Rod Poland,
  Director of Corp. Communications
• Amy Rocklin Ph.D.,
  VP & Gen. Counsel
• Sarah Demey,
  Admin. Mang.
• Bruce Papesh,
  Director
• A Charles Fischer,
  Director
• Richard E Jr Calk,
  President & COO
• Richard T Crowder,
  Director
• Jack C Parnell,
  Director
• Clayton K Yeutter,
  Director
• Thomas H Reed,
  Director
• Terri A Morrical,
  
• David H. Naemura,
  Chief Financial Officer
• Edward Bradley,
  V.P. Sales and Marketing
• Aashima Gupta,
  Director
• Jeffrey D Capello,
  Director
• Rex L Hamilton,
  Vice President
• Herbert D Doan,
  Director
• Gordon E Guyer,
  Director
• James L Herbert,
  Director
• Joseph M Madden,
  V.P. Scientific Affairs
• Richard R Current,
  Vice President & CFO
• Anthony E Maltese,
  VP Business Development
• Kenneth V Kodilla,
  Vice President
• Lon M Bohannon,
  COO
• Mark A Mozola,
  Vice President of R&D
• Leonard E Heller,
  Director
• Robert M Book,
  Director
• Stephen K. Snyder,
  Former Pres. and COO
• Paul S Satoh,
  V.P Research and Development
• Rafael A Rodriguez,
  Director
• Catherine E Woteki,
  Director
• Amy M Rocklin,
  Chief Legal Officer
• John Patrick Moylan,
  Chief Accounting Officer